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Objective: The signaling protein p38 mitogen-activated protein kinase is required for inﬂammatory
signaling in chondrocytes that regulates matrix metalloproteinase (MMP) production. We sought to
determine the role of speciﬁc p38 isoforms in chondrocyte catabolic signaling in response to IL-1b and
ﬁbronectin fragments (Fn-f).
Methods: Human articular chondrocytes isolated from normal ankle cartilage from tissue donors or from
osteoarthritic knee cartilage obtained during knee replacement were stimulated with IL-1b or Fn-f, with
or without pretreatment with p38 inhibitors (SB203580 or BIRB796) or growth factors (IGF-1 and OP-1).
p38 isoform phosphorylation was measured by antibody array and immunoblotting. MMP-13 expression
was measured by real-time polymerase chain reaction (PCR), enzyme-linked immunosorbent assay
(ELISA), and immunoblotting. Chondrocytes were transfected with plasmids expressing constitutively
active (CA) p38g or with adenovirus expressing dominant negative (DN) p38g.
Results: Stimulation of chondrocytes with either IL-1b or Fn-f led to enhanced phosphorylation of p38a
and p38g, with little phosphorylation of p38b or p38d isoforms. p38a localized to the nucleus and p38g
to the cytosol. Inhibition of both p38a and p38g with BIRB796 resulted in less inhibition of MMP-13
production in response to IL-1b or FN-f than did inhibition of only p38a with SB203580. Transfection
with CA p38g resulted in decreased MMP-13 production while transduction with DN p38g resulted in
increased MMP-13 production. IGF-1 and OP-1 pretreatment inhibited p38a phosphorylation but not
p38g phosphorylation.
Conclusions: p38g is activated by catabolic stimulation of human articular chondrocytes, but interestingly
suppresses MMP-13 production. Treatments that increase p38g activation may be of therapeutic beneﬁt
in reducing chondrocyte production of MMP-13.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The p38 mitogen-activated protein kinases (MAPKs) are serine/
threonine kinases that, when activated, transmit extracellular
signals to the cell nucleus. The p38 MAPK family is an important
mediator of inﬂammatory processes including regulation of the
signaling pathway activated by IL-1b1. There are four known p38
isoforms (p38a, p38b, p38g, and p38d). The ﬁrst isoform to be
described was p38a, which was shown to be involved in the
production of the inﬂammatory cytokines IL-1b and TNF-a in
response to lipopolysaccharide (LPS) stimulation of human mono-
cytes2. Subsequent reports identiﬁed p38b3, which shares 75%Richard F. Loeser, Section of
of Medicine, Medical Center
-1214.
.
s Research Society International. Pidentity with p38a and the less similar p38g4 and p38d5, which
both sharew60% identity with p38a. All isoforms are activated by
dual phosphorylation at Thr180 and Tyr182 residues, but they differ
in regards to the type of extracellular stimulus that results in
activation, in tissue distribution, and in cellular function.
IL-1b stimulates chondrocytes to secrete a number of proteases
that degrade articular cartilage matrix proteins. This matrix degra-
dation leads to the production of matrix fragments that include
ﬁbronectin fragments (Fn-f) (reviewed inRef. 6). These fragments can
in turn stimulate chondrocytes via the a5b1 integrin to produce
degradative enzymes, amplifying the already destructive stimulation
received from IL-1b. One of themost important proteases involved in
matrix degradation induced by IL-1b and Fn-f is MMP-13 (collage-
nase-3). This enzyme is responsible fordegradationof type II collagen
and is highly expressed in the pathological contexts of osteoarthritis7
and rheumatoid arthritis8. Stimulation of MMP-13 production by
either IL-1b9 or Fn-f10e12 has been shown to require p38 activity.
These earlier studies used chemical inhibitors and expression ofublished by Elsevier Ltd. All rights reserved.
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not speciﬁcally address which p38 isoforms were required.
A recent report has indicated the presence of all four p38 iso-
forms within inﬂamed synovial tissue but p38a and p38gwere the
predominantly expressed isoforms and were the most highly
phosphorylated suggesting they were more active13. To our
knowledge, it has not been determined which particular p38 iso-
forms are activated in chondrocytes in response to inﬂammatory
stimuli. One report has demonstrated the possible involvement of
p38b in the synthesis of mPGES-1, an enzyme involved in the
production of prostaglandin E2 in chondrocytes14. Another recent
report has shown upregulation of p38d gene expression in response
to type II collagen fragment stimulation of chondrocytes15. But
apart from these studies, we could not ﬁnd evidence for p38 iso-
form speciﬁc activation in chondrocytes or information on the role
of these isoforms inmediating downstream signaling that regulates
MMP expression. Therefore, the initial aim of the present study was
to determine which p38 isoforms are activated by inﬂammatory
stimulation of articular chondrocytes. We found that p38a and
p38g were the predominant isoforms phosphorylated in response
to IL-1b and FN-f. Since p38g function had not been studied
previously in chondrocytes, we focused further experiments on its
involvement in MMP-13 production.
Methods
Materials
Phospho-p38 (pan), p38a, phospho-MK2, phospho-HSP27 and
HA antibodies were from Cell Signaling (Beverly, MA). p38g anti-
body, recombinant IL-1b, pro-MMP-13 enzyme-linked immuno-
sorbent assay (ELISA) (detects MMP-13 that has not been processed
and activated), phospho-p38g ELISA, and the Human phospho-
MAPK Array kit were from R&D Systems (Minneapolis, MN). MMP-
13 antibody was from Anaspec (San Jose, CA). Recombinant IGF-1
was from Austral Biologicals (San Ramon, CA) and recombinant OP-
1 was a gift from Dr. Susan Chubinskaya at Rush University Medical
School (Chicago, IL). Nuclear and cytoplasmic extracts were made
using the NE-PER Nuclear and Cytoplasmic Extraction Reagents
from Pierce Biotechnology (Rockford, IL). p38 inhibitor SB203580
was purchased from EMDBiosciences (San Diego, CA). p38 inhibitor
BIRB79616 was purchased from the Medical Research Council
Protein Phosphorylation Unit at the University of Dundee (Dundee,
Scotland, UK). Real-time polymerase chain reaction (PCR) primers
for glyceraldehyde phosphate dehydrogenase (GAPDH), MMP-13,
p38 isoforms, and SybrGreen PCRMastermixwere from SuperArray
Biosciences (Frederick, MD). Recombinant ﬁbronectin fragment
(FN7-10) which contains the RGD a5b1 integrin binding site17 was
provided by Dr. Harold Erickson of Duke University (Durham, NC).
Tissue acquisition and chondrocyte cell culture
Human ankle cartilage was obtained from tissue donors within
48 h of death through the Gift of Hope Organ and Tissue Donor
Network (Elmhurst, IL) or from the National Disease Research
Interchange (Philadelphia, PA) in accordance with institutional
protocol. Each donor specimen was graded for degenerative
changes based on the 5-point Collins scale, as modiﬁed by Mueh-
leman et al.18. The OA cartilage was discarded tissue obtained after
knee replacement surgery. Cartilage was dissected from the joints
and digested in a sequential manner with Pronase and then over-
night with collagenase, as previously described10. Viability of iso-
lated cells was determined using trypan blue, and cells were
counted using a hemocytometer. Monolayer cultures were estab-
lished by plating cells in six-well plates at 2106 cells/mL inDulbecco’s modiﬁed Eagle’s medium (DMEM)/Ham’s F-12 medium
supplementedwith 10% fetal bovine serum. Platesweremaintained
forw5e7 days, with feedings every 2 days until they reached 100%
conﬂuence prior to experimental use.
Immunoblotting
Conﬂuent cells in monolayer were switched to serum-free
media. The following day cells were pretreated for 30 min with or
without inhibitors before stimulationwith either 10 ng/mL IL-1b or
500 nM Fn-f for 30 min. SB203580was tested at concentrations of 1,
5, and 10 mM and BIRB796 was used at concentrations of 0.1, 0.25,
and0.5 mM.CellswerewashedwithPBS and treatedwith lysis buffer
that contained 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM ethylene
diamine tetraacetic acid (EDTA), 1 mM ethylene glycol tetraacetic
acid (EGTA), 1% Triton X-100, 2.5 mM tetrapyrophosphate, 1 mM
glycerol phosphate, 1 mM Na3VO4, 1 ml/mL leupeptin, and 1 mM
phenylmethylsulfonyl ﬂuoride. Lysates were centrifuged to remove
insoluble material, and the soluble protein concentration was
determined with BCA reagent (Pierce). Samples containing equal
amounts of total proteinwere separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), transferred to
nitrocellulose, and probed with appropriate antibodies.
An antibody array that detects phosphorylated MAPK family
members was also performed on chondrocyte lysates after stimu-
lation with 10 ng/mL IL-1b or 500 nM Fn-f. Because the phos-
phorylation site is similar in the different p38 isoforms, this array
uses isoform speciﬁc antibodies that are not phosphorylation-
speciﬁc to capture the various p38 isoforms followed by a pan anti-
phospho-p38 antibody to detect the phosphorylated protein.
For MMP-13 immunoblotting, cells were pretreated with
inhibitors 30 min prior to stimulation with either IL-1b or Fn-f
overnight. Media was then collected from cells and run on SDS-
PAGE as above.
Cytosol and nuclear preparations
Cells in monolayer were switched to serum-free media. The
following day, cells were stimulated with IL-1b for 5 and 30 min.
Cells were then removed from monolayer by scraping in ice cold
PBS then cytosol and nuclear preparations were made using the
NE-PER kit (Pierce). Protease and phosphatase inhibitors were
included in lysis buffers when making fractions.
Real-time PCR analysis
Total RNA was isolated using the RNeasy Mini Kit (Qiagen,
Valencia, CA). Two micrograms of RNA were reverse transcribed
using an avian myeloblastosis virus (AMV) reverse transcriptase
and oligo dT primer at 42C for 1 h. 1 mL of RT reaction was then
combined in a reaction mixture with 1 mL of MMP-13 speciﬁc
primer pair, 12.5 mL 2 SybrGreen PCR Mastermix, and water to
a ﬁnal reaction volume of 25 mL. Reactions were then run in
duplicate with 40 cycles of ampliﬁcation on an ABI Prism 7000 real-
time PCR machine (Applied Biosystems). The amount of MMP-13
mRNA was normalized against levels of GAPDH mRNA using data
from parallel reactions run with GAPDH primers. All data were
analyzed using the Comparative CT Method.
Plasmids and cell transfection
Plasmid expressing a constitutively active (CA) form of p38g
that is rendered active by mutation (p38gD179A) as described
previously19 was kindly provided by Dr. David Engelberg (Hebrew
University of Jerusalem). Plasmids were transfected into
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described previously20. Cells were allowed to recover for 24 h in
media supplemented with 20% serum before being switched to
media with 10% serum for subsequent experimentation.
Adenoviral transduction
Adenovirus expressing DN p38g was obtained from a commer-
cial source (Cell Biolabs, San Diego, CA). Primary human chon-
drocytes were plated at a density of 1106 cells per well in 12-well
plates. The cells were then infected with adenovirus encoding p38g
DN construct using calcium chloride to enhance transduction efﬁ-
ciency. Null control adenovirus was used as a negative control. Two
hours after the transduction, the cells were fed with complete
media and incubated for 48 h at 37C in a humidiﬁed environment
containing 5% CO2. The cells were then changed to serum-free
conditions and incubated overnight prior to stimulation.
Statistics
Student’s t test (paired, two-tailed) was used for statistical
analysis.
Results
Phosphorylation of p38 isoforms in chondrocytes in response to
IL-1b and Fn-f stimulation
In initial experiments, we screened for the activation of
multiple MAPKs, including the four isoforms of p38, by using an
antibody array that detects phosphorylated forms of 27 different
proteins in the MAPK pathway. Phosphorylation of both p38a
and p38g increased in chondrocytes following stimulation with
either IL-1b or Fn-f [Fig. 1(A)]. Conversely, we could not detect
increased phosphorylation of either p38d or p38b. ERK1, ERK2,
JNK2, and HSP27 phosphorylation were also increased after
stimulation. We used immunoblotting after separation of
samples by SDS-PAGE as a second method for analyzing p38
isoform phosphorylation. p38g runs at a slightly higherA
B
Fig. 1. p38a and p38g are phosphorylated in chondrocytes following catabolic stimulation. (
or with control media. Lysates were analyzed on a MAPK antibody array. Results are repre
10 ng/mL IL-1b. Lysates were immunoblotted with pan phosphospeciﬁc p38 antibody that
40 kD) are marked. Results are representative of three independent experiments.molecular weight (w45 kD) than p38a (w38 kD)16,21. Using an
antibody that recognizes the phosphorylated form of all four p38
isoforms (pan phospho-p38), we detected phosphorylation of
two bands after IL-1b stimulation, consistent with the molecular
weights of p38a and p38g [Fig. 1(B)].
Differential subcellular location of p38a and p38g after stimulation
with IL-1b and Fn-f
A previous study in cardiac myocytes demonstrated that p38a
and p38gmay display different subcellular localizations, with p38a
being both cytosolic and nuclear and p38g found primarily in the
cytosol22. An additional report has suggested that differential
localization of the two isoforms may be related to their phos-
phorylation status23. This differential localization suggests that the
two isoforms may have different cellular functions. We performed
cytosol/nuclear protein fractionation on chondrocytes after stim-
ulation with IL-1b or FN-f, followed by immunoblotting with iso-
form speciﬁc antibodies for p38a and p38g that recognize both the
phosphorylated and non-phosphorylated forms of the proteins.
p38a was found within the nucleus of chondrocytes and the total
level of p38a was increased slightly between 0 and 30 min of
stimulation, while p38g was conﬁned to the cytosol and also
showed a minimal increase in total protein after stimulation
(Fig. 2). When using the isoform-speciﬁc antibody to total p38g,
two bands were consistently noted just below the 50 kD marker
(Fig. 2) and above the 40 kD marker (Fig. 1).
p38 inhibitors SB203580 and BIRB796 differentially inhibit p38g
and MMP-13 production in chondrocytes
The p38 inhibitor SB203580 is a well-characterized p38
inhibitor that inhibits p38a/b isoform activity without affecting
the activity of p38d/g isoforms24. This inhibitor has been used to
demonstrate that p38 is involved in the production of MMP-13
induced both by IL-19 and Fn-f10,12. There are, however, no
commercially available chemical inhibitors that target p38g
speciﬁcally. A recent report has indicated that the p38 inhibitor
BIRB796 can inhibit all four p38 isoforms and, when compared toA) Chondrocytes were stimulated for 30 min with either 10 ng/mL IL-1b or 500 nM Fn-f
sentative of three independent experiments. (B) Chondrocytes were stimulated with
recognizes all isoforms. Anticipated locations of p38g (above 40 kD) and p38a (below
Fig. 2. p38a is localized to the nucleus and p38g to the cytosol. Chondrocytes were stimulated with IL-1b or FN-f for 5 and 30 min. Cytosolic and nuclear fractions were immu-
noblotted with antibodies speciﬁc for total p38a or p38g isoforms. Blots were stripped and immunoblotted with Lamin B as a nuclear marker protein to conﬁrm separation of
nuclear from cytosolic proteins. Results are representative of three independent experiments.
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order to determine functions of p38g in chondrocytes using these
inhibitors, we ﬁrst sought to characterize their activities in our
system. In initial experiments, we conducted a dose response
curve for each inhibitor with a 30 min inhibitor pretreatment
prior to 30 min IL-1b stimulation. To determine the activity of the
p38a isoforms, we analyzed phosphorylation of HSP27 by
immunoblotting. HSP27 is a substrate of MK2, which is down-
stream of p38a and not p38g25 and is a marker of p38a activity.
Increasing amounts of each inhibitor led to a decreased phos-
phorylation of HSP27 [Fig. 3(A)]. Densitometric analysis showed
that at a dose of 10 mM SB203580 and 0.5 mM BIRB796 phos-
phorylation of HSP27 was inhibited to the same degree [Fig. 3(B)],
conﬁrming equal inhibition of p38a activity by each inhibitor at
these doses. The selected doses were then used to test inhibitor
effect on p38g activity. We ﬁrst checked phosphorylation of p38g
using an ELISA speciﬁc for phosphorylated p38g. IL-1b stimulated
phosphorylation of p38g and this stimulation was not inhibited byA B
C D
Fig. 3. Effects of the p38 inhibitors SB203580 and BIRB796 on p38a and p38g activity. (A) C
stimulation with IL-1b. Lysates were then immunoblotted with phosphospeciﬁc HSP27 ant
tometric analysis was performed to determine intensity of the phosphorylated HSP27 band.
10 mM SB203580 or 0.5 mM BIRB796 prior to IL-1b stimulation. Lysates were measured with
three independent experiments. (D) Chondrocytes were pretreated with 10 mM SB203580 or
speciﬁc antibody. Immunoprecipitates were then used in an in vitro kinase assay using recSB203580 pretreatment, but was reduced by about 50% with
BIRB796 pretreatment [Fig. 3(C)]. We next performed a kinase
assay with immunoprecipitated p38g using recombinant ATF-2 as
a substrate to determine inhibitor effect on p38g activity. IL-1b
stimulated p38g kinase activity and this activity was not inhibited
by SB203580 pretreatment, but was inhibited by BIRB796
pretreatment [Fig. 3(D)]. We also checked phosphorylation of
JNK2 to rule out the possibility of off target inhibitor effects. At
the dose of BIRB796 used in the present studies (0.5 mM), no effect
on IL-1 stimulated JNK2 phosphorylation was noted (data not
shown). Collectively, these experiments conﬁrm that the inhibi-
tors are performing as expected, with SB203580 inhibiting the
activity of p38a but not p38g and BIRB796 inhibiting the phos-
phorylation and activity of both p38a and p38g.
Chondrocytes were next pretreated with the inhibitors for
30 min prior to overnight stimulation with either IL-1b or Fn-f
in order to determine the ability of the inhibitors to block
MMP-13 expression and production. RNA was extracted forhondrocytes were pretreated with the indicated doses of SB203580 or BIRB796 prior to
ibody. (B) Immunoblots from two independent experiments were scanned and densi-
Results are means and 95% conﬁdence intervals. (C) Chondrocytes were pretreated with
an ELISA for phosphorylated p38g. Results are mean and 95% conﬁdence intervals of
0.5 mM BIRB796 prior to IL-1b stimulation. Lysates were immunoprecipitated with p38g
ombinant ATF-2 as a substrate.
Fig. 4. Effects of the p38 inhibitors SB203580 and BIRB796 on IL-1 and FN-f stimulation of MMP-13. Chondrocytes were pretreated with either 10 mM SB203580 or 500 nM BIRB796
for 30 min prior to overnight stimulation with either 10 ng/mL IL-1b or 500 nM Fn-f. (A) Media was collected and an ELISA was run for pro-MMP-13 (n¼ 5, mean 95% conﬁdence
intervals) or media was immunoblotted with MMP-13 antibody (B). (C) RNA was harvested in parallel to media collection and real-time PCR was run with MMP-13 primers in
duplicate samples. Results were normalized to GAPDH as a housekeeping gene (n¼ 2, mean 95% conﬁdence intervals).
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ELISA and immunoblotting. p38a inhibition with SB203580
dramatically inhibited MMP-13 induced by either IL-1b or Fn-f
at both the protein [Fig. 4(A, B)] and RNA levels [Fig. 4(C)]. The
combined inhibition of p38a and p38g with BIRB796 also
reduced MMP-13 expression and production but interestingly
was less effective than inhibiting only p38a with SB203580.
Inhibition of p38a without inhibition of p38g might be more
effective at inhibiting MMP-13 expression than inhibiting both
isoforms if p38g was serving as a negative regulator of MMP-13
expression rather than a positive regulator. This possibility was
tested next.
Transfection of osteoarthritic chondrocytes with CA p38g reduces
MMP-13 production
Since osteoarthritic chondrocytes produce high amounts of
endogenous MMP-1326, we decided to use these cells to deter-
mine if expression of CA p38g19 could downregulate MMP-13
expression. Transfection of an HA-tagged construct was
conﬁrmed by immunoblotting transfected cells with HA antibody
and phosphospeciﬁc p38 antibody (data not shown). Transfection
with the active p38g construct decreased MMP-13 production by
OA chondrocytes [Fig. 5(A)]. Since we showed that p38g trans-
fection was able to downregulate endogenous MMP-13 produc-
tion in OA cells, we next wanted to see if p38g transfection could
inhibit the production of MMP-13 induced by either IL-1b or Fn-f
in normal cells. Active p38g transfection was able to down-
regulate MMP-13 production induced by either stimulus [Fig. 5
(B)]. We next obtained an adenovirus that expresses a DN form
of p38g. We infected chondrocytes with this virus and 48 h later
stimulated cells with either Fn-f or IL-1. Stimulated chondrocytes
expressing DN p38g had increased MMP-13 production whencompared to an adenovirus control [Fig. 5(C)] consistent with the
hypothesis that p38g serves as a negative regulator of MMP-13
expression.
The growth factors IGF-1 and OP-1 inhibit p38a but not p38g
phosphorylation induced by IL-1b or Fn-f
In a previous report27, we demonstrated that the growth factor
combination of IGF-1 and OP-1 was able to signiﬁcantly block
chondrocyte MMP-13 production induced by IL-1b or Fn-f stimu-
lation. We decided to determine if this growth factor combination
might affect p38a and p38g differentially. In the present study,
pretreatment with the same growth factor combination decreased
p38a phosphorylation induced by either IL-1b or Fn-f and reduced
phosphorylation of MK2 which is downstream of p38a [Fig. 6(A)].
Because of the lower amounts of phospho-p38g in chondrocytes,
we were not able to consistently measure effects of the growth
factors on p38g phosphorylation by immunoblotting and so used
the more sensitive ELISA method. Unlike p38a, p38g phosphory-
lation was not signiﬁcantly different in cells pretreated with the
growth factors followed by either IL-1b or FN-f stimulation
consistent with differential inhibition of p38a and p38g by IGF-I
plus OP-1 [Fig. 6(B)].
Discussion
We show that both p38a and p38g isoforms, but not p38b or
p38d isoforms, are phosphorylated in response to catabolic stim-
ulation of human articular chondrocytes with either IL-1b or
recombinant Fn-f. Both IL-1 and FN-f have been previously shown
to activate signaling pathways that require p38 activation for the
increased production of MMPs9e12. In the present study, we found
that the p38g isoform may act as a negative feedback regulator of
Fig. 5. Effects on chondrocyte MMP-13 production after overexpression of CA and DN p38g. (A) Osteoarthritic chondrocytes were transfected with 3 mg constitutively active (CA)
HA-tagged p38g plasmid or empty plasmid vector as a control. 48 h after transfection, media was collected and pro-MMP-13 was measured by an ELISA. Results are the mean 95%
conﬁdence intervals of three independent experiments. (B) Normal human chondrocytes were transfected with 3 mg CA p38g plasmid or empty plasmid vector as a control. 48 h
after transfection cells were stimulated with either 10 ng/mL IL-1b or 500 nM Fn-f overnight. Media was collected and MMP-13 was measured by immunoblotting. Bands from the
IL-1b experiment were from the same gel run at the same time and were spliced together (indicated by a line) due to being in noncontiguous lanes. (C) Chondrocytes were infected
with adenovirus expressing DN p38g or non-expressing adenovirus as a control. 48 h later cells were stimulated with either 10 ng/mL IL-1b or 500 nM Fn-f overnight. Media was
collected and MMP-13 was measured by ELISA. Results are the mean and 95% conﬁdence intervals of three independent experiments for IL-1b and two experiments for Fn-f.
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stimulation.
p38a is the predominant isoform expressed in many tissues
whereas p38g expression is more limited. A previous study
comparing expression in heart, brain, placenta, lung, liver, skeletal
muscle, kidney, and pancreas noted p38a in all the tissues studiedFig. 6. Effects of IGF-1 plus OP-1 on IL-1 and FN-f induced p38 and MK2 phosphorylation. Ch
stimulation with either 10 ng/mL IL-1b or 500 nM Fn-f. (A) Samples were immunoblotted w
stripped and immunoblotted with actin antibody as a loading control. (B) Lysates were ana
conﬁdence intervals of three independent experiments.but p38g only in skeletal muscle4. Our immunoblotting results,
using antibodies that recognize p38g, with chondrocyte lysates
demonstrated that chondrocytes do contain easily detectable
amounts of the p38g in addition to p38a. By real-time PCR we
have detected expression of all four p38 isoforms with
p38g> p38a p38b> p38d (unpublished observations).ondrocytes were pretreated with 100 ng/mL IGF-1 plus 100 ng/mL OP-1 prior to 30 min
ith pan phosphospeciﬁc p38 antibody and phosphospeciﬁc MK2 antibody. Blots were
lyzed with an ELISA that measures phosphorylated p38g. Results are the mean 95%
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depends on a balance of activity in multiple signaling pathways.
By immunoblotting, the relative amount of phosphorylated p38a
in IL-1b and FN-f stimulated human articular chondrocytes was
much greater than the amount of phosphorylated p38g suggesting
that these catabolic stimuli alter the balance in favor of p38a and
this results in increased MMP-13 expression. p38a has been
shown previously to be a positive regulator of MMP-13 production
in carcinoma cells28 and the previous studies of IL-1 and FN-f
stimulation in chondrocytes showed that inhibition of p38a with
SB203580 or DN constructs inhibited MMP-13 expression9e12. Of
interest, when chondrocytes were pretreated with IGF-I and OP-1,
which inhibit IL-1 and FN-f induced MMP-1327, the phosphoryla-
tion of p38a but not p38g was inhibited which would alter the
balance towards p38g which may at least partially contribute to
inhibition of MMP-13 expression. Further studies would be
needed to determine if IGF-I and OP-1 are affecting other path-
ways as well.
We were not able to determine the mechanism for the negative
MMP-13 regulationbyp38g. Sincep38gappeared tobe located in the
cytosol andnot thenucleus it is unlikely to be a direct effect onMMP-
13 transcription. The balance of the phosphorylation of the two p38
isoforms could controlMMP-13expression through regulationofAP-
1 activity. MMP-13 transcription induced by both IL-1b9 and Fn-f11 is
dependent on AP-1 activation. Activation of p38g has been found to
decrease theactivationofAP-1 inother cell types29,30. Also consistent
with a role forAP-1modulation is theﬁnding that the combinationof
IGF-1 plus OP-1 inhibited p38a but not p38g phosphorylation. We
hadpreviously shown this growth factor combination inhibitedAP-1
activation and subsequent MMP-13 expression27.
In previous reports, it has been demonstrated that p38a and
p38g phosphorylate different downstream targets. An early report
indicated that MK2 is a downstream target of p38a, but not p38g25.
We found that IL-1b or FN-f stimulated MK2 phosphorylation and
this was inhibited by blocking p38a with SB203580. Interestingly,
several reports have implicated MK2 in the arthritis disease
process. One report indicated MK2 deﬁcient mice showed a resis-
tance to collagen-induced arthritis31. Another report showed that
suppression of MK2 expression in chondrocytes led to decreased
production of MMP-13 and decreased prostaglandin E2 release32. If
p38a and p38g differentially phosphorylate and activate MK2 in
chondrocytes, this may at least partially explain their different
effects on MMP-13 production.
There are multiple kinases that can activate p38a33 while less is
known about speciﬁc p38g activation. However, selective activation
of p38 isoforms has been reported and has been shown to be
mediated by the complexes formed between the kinases that
activate p38 (MAPK kinases or MKKs) and the speciﬁc p38 iso-
forms34. Although MKK6 can activate either p38a or p38g, prefer-
ential activation of p38a has been noted such that lower levels of
MMK6 activity result in activation of p38a and much higher levels
are needed before p38g is activated35.
In summary, our data show that activation of p38gmay decrease
production of MMP-13 in human chondrocytes. Further studies are
indicated to determine the mechanism for this effect which differs
signiﬁcantly fromp38a. To date, the studies that have focused onp38
inhibition as a potential therapy for arthritis have not consideredp38
isoform speciﬁcity. A recent study demonstratedmore severe, rather
than less severe, OA-like changes in mice expressing a DN p38
construct under control of the type II collagen promoter36. The DN
construct used in that study had mutations in the p38 phosphory-
lation sites (Thr180 andTyr182) that are required to activatep38. Itwas
notdetermined if this construct speciﬁcally inhibitedp38aactivation
or if p38g, which shares the activating phosphorylation sites, may
also have been inhibited. Based on our ﬁndings, a therapeuticapproach to inhibit cartilage degradation would be to alter the
balance in p38 activity to favor p38g over p38a.
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